PMID- 33456123
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20240330
IS  - 1333-9451 (Electronic)
IS  - 0353-9466 (Print)
IS  - 0353-9466 (Linking)
VI  - 59
IP  - 2
DP  - 2020 Jun
TI  - ADROPIN - POTENTIAL LINK IN CARDIOVASCULAR PROTECTION FOR OBESE MALE TYPE 2 
      DIABETES MELLITUS PATIENTS TREATED WITH LIRAGLUTIDE.
PG  - 344-350
LID - 10.20471/acc.2020.59.02.19 [doi]
AB  - The aim of this study was to determine plasma adropin concentration and 
      parameters of insulin resistance in obese male type 2 diabetes mellitus (T2DM) 
      patients before and after 3-month liraglutide treatment. In this interventional 
      study, we enrolled 15 obese male T2DM patients with body mass index (BMI) >35 
      kg/m(2), uncontrolled disease and HbA(1c) >7.5%, having previously taken taking 
      two oral antidiabetic drugs. We modified their therapy to metformin and 
      liraglutide for the next three months. After three months of liraglutide 
      treatment, we observed significant decrease in body weight (from 111.5+/-18.7 kg to 
      109.2+/-17.5 kg, p=0.016) and BMI (from 40.9+/-7.3 to 40.1+/-7.0 kg/m(2), p=0.021). 
      Plasma adropin concentration increased significantly (p=0.003) compared with 
      baseline. Fasting plasma insulin level decreased from 17.79+/-6.53 to 13.38+/-3.51 
      mU/L (p=0.002), fasting plasma glucose level decreased from 8.66+/-3.07 to 
      7.41+/-2.21 mmol/L (p=0.004) and HbA(1c) decreased from 7.98+/-0.70% to 7.26+/-0.36% 
      (p=0.003). Insulin resistance presented as HOMA-IR decreased significantly from 
      7.30+/-5.19 to 4.52+/-2.61 (p=0.002). Systolic blood pressure, lipid status, liver 
      and kidney function improved, but not reaching statistical significance. Treating 
      obese male T2DM patients with liraglutide resulted in a significantly higher 
      plasma adropin concentration, significant weight loss and improved parameters of 
      insulin resistance, i.e. decreased fasting plasma insulin, plasma glucose levels 
      and HOMA-IR.
FAU - Ticinovic Kurir, Tina
AU  - Ticinovic Kurir T
AD  - 1Department of Endocrinology and Diabetes, Split University Hospital Centre 
      Split, Croatia; 2Department of Pathophysiology, University of Split School of 
      Medicine, Split, Croatia.
FAU - Milicevic, Tanja
AU  - Milicevic T
AD  - 1Department of Endocrinology and Diabetes, Split University Hospital Centre 
      Split, Croatia; 2Department of Pathophysiology, University of Split School of 
      Medicine, Split, Croatia.
FAU - Novak, Anela
AU  - Novak A
AD  - 1Department of Endocrinology and Diabetes, Split University Hospital Centre 
      Split, Croatia; 2Department of Pathophysiology, University of Split School of 
      Medicine, Split, Croatia.
FAU - Vilovic, Marino
AU  - Vilovic M
AD  - 1Department of Endocrinology and Diabetes, Split University Hospital Centre 
      Split, Croatia; 2Department of Pathophysiology, University of Split School of 
      Medicine, Split, Croatia.
FAU - Bozic, Josko
AU  - Bozic J
AD  - 1Department of Endocrinology and Diabetes, Split University Hospital Centre 
      Split, Croatia; 2Department of Pathophysiology, University of Split School of 
      Medicine, Split, Croatia.
LA  - eng
PT  - Journal Article
PL  - Croatia
TA  - Acta Clin Croat
JT  - Acta clinica Croatica
JID - 9425483
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Aged
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glycated Hemoglobin
MH  - Humans
MH  - *Hypoglycemic Agents/therapeutic use
MH  - Insulin
MH  - *Liraglutide/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - *Obesity/complications
PMC - PMC7808222
OTO - NOTNLM
OT  - Adropin
OT  - Diabetes mellitus type 2
OT  - Endothelial cell dysfunction
OT  - Insulin resistance
OT  - Liraglutide
OT  - Obesity
EDAT- 2021/01/19 06:00
MHDA- 2021/01/26 06:00
PMCR- 2020/06/01
CRDT- 2021/01/18 05:27
PHST- 2021/01/18 05:27 [entrez]
PHST- 2021/01/19 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/06/01 00:00 [pmc-release]
AID - acc-59-344 [pii]
AID - 10.20471/acc.2020.59.02.19 [doi]
PST - ppublish
SO  - Acta Clin Croat. 2020 Jun;59(2):344-350. doi: 10.20471/acc.2020.59.02.19.